NCT02170974View on ClinicalTrials.gov

Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

August 31, 2004

Conditions
Healthy
Interventions
DRUG

BIBR 1048 MS polymorph II

DRUG

BIBR 1048 MS polymorph I

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY